Will IBRX Q2 2026 net product revenue exceed $45 million?
Current Prediction
Prediction History
Baseline 0.72 reflected uncertainty about whether Q1 would hit ~$44-46M. The Q1 print of $44.2M confirmed the trajectory and made the Q2 threshold a near-baseline continuation scenario. Bumped to 0.82.
Why This Question Matters
Revenue trajectory is the central question for both commercial viability and financing leverage. The Gravy Gauge flagged CONDITIONAL durability with growth dependent on continued adoption. If Q2 revenue exceeds $45M (continuing 15%+ QoQ growth), it validates the adoption thesis and strengthens financing position. If growth decelerates below this level, it signals approaching market ceiling.
Prediction Distribution
Individual Predictions(9 runs)
Q1 2026 came in at $44.2M vs. Q4 2025's $38.3M (15% QoQ). To hit $45M in Q2 requires only ~2% QoQ growth from Q1, far below the observed trend. Even meaningful deceleration would clear the threshold. The IDMC-confirmed enrollment and NCCN Guidelines inclusion support continued physician adoption.
Revenue trajectory is increasingly predictable. Base case: Q2 at $48-51M (10-15% QoQ extension). Downside case: flat QoQ at $44.2M (still misses by $0.8M). The binary threshold is essentially a question of whether growth stalls completely — which is not supported by the unit volume trajectory or guideline tailwinds.
The deceleration pattern (Q3→Q4: 20%, Q4→Q1: 15%) suggests Q1→Q2 at 10-13%, giving $48.6-49.9M. For a miss, Q2 growth must be below 2% QoQ, representing a sharp discontinuity not supported by any current evidence. FDA warning letter affects narrative, not physician prescribing.
The Q1 2026 $44.2M print makes this market near-certain at first glance, but there's residual risk: inventory destocking, gross-to-net adjustments, or a brand-reputation effect from the warning letter could compress Q2. Still, the base rate favors clearing $45M by a comfortable margin.
Unit volume growth of 168% YoY mirrors dollar growth, indicating price stability. Even minimal continued volume expansion in Q2 clears the threshold. The NCCN inclusion is specifically for papillary-only use, which expands the addressable prescription within the current approved indication.
Threshold only 2% above Q1 print. Historical launch curves for specialty oncology biologics rarely show sequential declines in the 5-8 quarter post-launch window unless there is a safety issue or competitor entry. Neither present here.
Q1 came in at $44.2M. Threshold is $45M. Needs 2% growth. Almost certain.
Strong growth trajectory. NCCN tailwind. Warning letter unlikely to affect prescribing directly. High probability.
Base rate for sequential growth in launching biologic strongly favors continued growth. Q2 should clear $48M comfortably.
Resolution Criteria
Resolves YES if IBRX reports Q2 2026 (quarter ending June 30, 2026) net product revenue of $45 million or more in its 10-Q or earnings press release.
Resolution Source
IBRX 10-Q for Q2 2026 or earnings press release
Source Trigger
ANKTIVA quarterly revenue growth rate below 10% QoQ
Full multi-lens equity analysis